• Article

Real-world treatment patterns and clinical outcomes in Er+/Her2- metastatic breast cancer Results from a multicountry retrospective medical record review

Although ET is the recommended treatment for most patients with ER+/HER2– MBC, a substantial proportion received CT, possibly due to the high prevalence of visceral disease in the study population. Median TTP on current therapies is < 1 year. These findings suggest a continuing unmet need for new treatments that extend TTP.

Citation

Mitra, D., Kurosky, S., Zanotti, G., & Kaye, J. (2016). Real-world treatment patterns and clinical outcomes in Er+/Her2- metastatic breast cancer: Results from a multicountry retrospective medical record review. Value in Health, 19(3), A137. https://doi.org/10.1016/j.jval.2016.03.1644